Skip to content

Effects of Liposomal Bupivacaine Versus Conventional Bupivacaine for Interscalene Brachial Plexus Block on Quality of Recovery After Major Shoulder Surgery.

Effects of Liposomal Bupivacaine Versus Conventional Bupivacaine for Interscalene Brachial Plexus Block on Quality of Recovery After Major Shoulder Surgery.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122807
Enrollment
Unknown
Registered
2026-04-17
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain after shoulder joint surgery

Interventions

Liposomal bupivacaine + bupivacaine hydrochloride group:133mg of liposomal bupivacaine (10mL) +25mg of bupivacaine hydrochloride (5mL
concentration 0.5%), the total volume after mixing is 15mL.Perform intermuscular groove brachial plexus block
The bupivacaine hydrochloride group was used alone:75mg of bupivacaine hydrochloride, with a total volume of 15mL and a concentration of 0.5%.Perform intermuscular groove brachial plexus block

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ASA classification I to III; 2. 18 years old or above; 3. Plan to undergo elective major shoulder surgery (rotator cuff repair or total shoulder replacement).

Exclusion criteria

Exclusion criteria: 1. Allergic or intolerant to amide local anesthetics; 2. There is objective evidence of nerve injury in the affected upper limb; 3. Mental or cognitive impairments that may affect perioperative assessment; 4. Recent (<3 months) history of drug or alcohol abuse; 5. There is already a coagulation dysfunction; 6. Receive opioid drug treatment simultaneously; 7. Had undergone surgery on the contralateral shoulder joint within 12 months prior to randomization; 8. Participated in another research trial involving the investigational drug product within 6 months prior to randomization; 9. Infection at the injection site; 10. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Postoperative QoR-15 score;

Secondary

MeasureTime frame
QoR-15 score;Postoperative inflammatory factors (IL-1, IL-6, IL-10, TNF);NRS rating;

Countries

China

Contacts

Public ContactXintao Wang

Shanghai Sixth People's Hospital

wangxintaos@126.com+86 132 6262 6693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026